drugset
drugset / Trial / NCT01195038

Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed Adults

NCT01195038 ↗

Phase 2 Completed 87 enrolled UMN Pharma Inc.
Non-randomizedSingle-groupOpen-labelPrevention

Summary

The study is designed to assess the immunogenicity and safety of one booster vaccination with 45 μg of a recombinant H5N1 influenza (A/Indonesia/05/2005) HA vaccine in healthy young adults, previously primed with a two-vaccination of 3 different doses of a recombinant H5N1 influenza (A/Vietnam/1203/2004) HA vaccine in a priming study (JPIP501-01a, NCT00980447).

Timeline

Start
2010-10
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Recombinant Influenza HA Vaccine (H5N1) Vaccine 45 ug —

Indications

influenza